Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloda Metronomic vs Conventional Maintenance in mCRC
NCT02893540Phase 3Unknown
- Sponsor
- Ruijin Hospital
- Start
- Sep 2016
- Primary completion
- Dec 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in colorectal cancer (metastatic) (mCRC), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT02893540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893540.